ArticleBMC cardiovascular disorders2025
Impact of the hemoglobin-to-red cell distribution width ratio on 30-day readmission in patients with heart failure.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Creatinine-to-cystatin C ratio as muscle assessment tool and predictive value for mortality and sarcopenia in patients with chronic kidney disease: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- Joint analysis of hemoglobin-to-RDW and creatinine-to-albumin ratios for mortality prediction in critical heart failure.iScience · 2026Article
- Association of hemoglobin-to-red cell distribution width ratio with diabetic retinopathy risk and severity.Frontiers in endocrinology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting all-cause readmission in patients with heart failure (HF) is crucial. This study investigated the independent risk factors for short-term readmission and assessed the potential mediators involved in this process.
methodsWe evaluated data from 2,254 patients with HF admitted to our institution between January 2019 and December 2020. Logistic regression analysis was used to examine the association between sarcopenia index (SI), neutrophil-to-lymphocyte ratio (NLR), hemoglobin-to-red cell distribution width ratio (HRR), and all-cause 30-d readmission. A restricted cubic spline regression model with three knots assessed potential non-linear relationships between confounders and readmission risk. A mediation analysis was performed to evaluate the direct and indirect effects, as well as the proportion of mediation.
resultsThe mean age of the participants was 72 ± 12 years, with 1,324 males (58.7%). The all-cause 30-d readmission rate was 7.1%. HRR was independently associated with 30-d readmission among the evaluated biomarkers, whereas SI and NLR showed no significant correlation. A non-linear relationship was found between HRR and readmission risk, with an inflection point at 0.94. Patients with HRR < 0.94 exhibited a significantly higher risk of readmission, whereas no significant association was found for HRR ≥ 0.94. Mediation analysis revealed that N-terminal pro-B-type natriuretic peptide (NT-proBNP) partially mediated this relationship, which accounted for 13.6% of the effect.
conclusionsHRR is an independent predictor of all-cause 30-d readmission in patients with a non-linear relationship observed. An inverse association was found for HRR < 0.94, whereas no significant association was found for HRR ≥ 0.94. Additionally, NT-proBNP was identified as a partial mediator of this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.